Loading...

ASBP ASPIRE BIOPHARMA HOLDINGS INC Management Changes 8-K Filing

SPR

SBP

ASPIRE BIOPHARMA HOLDINGS INC

(ASBP)

2025 8-K

Securities Purchase Agreement

New Preferred Stock

Stock Incentive Plan

Director Resignation

Debt Exchange Agreement

New Stock Agreement

Stockholder Voting Results

Delisting Warning

Management Change

Securities Agreement

Appointements, Resignations

Management Changes

Debt Restructuring

Nasdaq Compliance

Merger Completion

Equity Line Agreement

Merger Approval

Merger Announcement

Merger Agreement

Funding Agreement

Merger Agreement

Merger Announcement

Merger Agreement

Termination of Merger Agree...

Amendment to Merger Agreement

Amendments to Articles of I...

Non-Redemption Agreement

Agreements and Meeting Post...

Postponement of Shareholder...

Merger Agreement

Purchase Agreement and Chan...

True-up Payment

Asset Acquisitions

EGM Approval of Charter Ame...

Non-Redemption Agreements

Non-Redemption Agreements

Non-Redemption Agreement

External Links:

On July 24, 2025, Aspire Biopharma Holdings, Inc. announced the resignations of CEO Michael Howe and independent director Gary Stein, with Kraig Higginson appointed as Interim CEO and Howard Doss as Audit Committee Chairman. Director Barbara Sher also resigned due to irreconcilable differences with company policies.

AI Assistant

ASPIRE BIOPHARMA HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.